The Food and Drug Administration (FDA) announces that Clarcon Biological Chemistry Laboratory Inc. of Roy, Utah, is voluntarily recalling some skin sanitizers and skin protectants marketed under several different brand names because of high levels of disease-causing bacteria found in the product during a recent inspection. The FDA is warning consumers to not use any Clarcon products.
Consumers should not use any Clarcon products and should throw these products away in household refuse. Analyses of several samples of over-the-counter topical antimicrobial skin sanitizer and skin protectant products revealed high levels of various bacteria, including some associated with unsanitary conditions. Some of these bacteria can cause opportunistic infections of the skin and underlying tissues. Such infections may need medical or surgical attention, and may result in permanent damage. Examples of products that should be discarded include:
-- Citrushield Lotion
-- Dermasentials DermaBarrier
-- Dermassentials by Clarcon Antimicrobial Hand Sanitizer
-- Iron Fist Barrier Hand Treatment
-- Skin Shield Restaurant
-- Skin Shield Industrial
-- Skin Shield Beauty Salon Lotion
-- Total Skin Care Beauty
-- Total Skin Care Work
Findings from the FDA’s recent inspection of the Clarcon facility are particularly concerning because the products are promoted as antimicrobial agents that claim to treat open wounds, damaged skin, and protect against various infectious diseases. The inspection uncovered serious deviations from FDA’s current Good Manufacturing Practice requirements.
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
Enhancing Poliovirus Surveillance: Key Insights for Infection Prevention Personnel
April 4th 2024The fight against poliovirus continues with renewed urgency as recent surveillance data reveals both progress and persistent challenges. In a critical update, infection prevention personnel are presented with key insights into the ongoing battle against this scourge.